Overview

Montelukast in Acute RSV Bronchiolitis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
There is evidence of inflammatory mechanisms in RSV bronchiolitis with increased cysteinyl-leukotrienes (cys-LT). Recently, specific cys-LT receptor antagonists - montelukast (Singulair©) approved for use in infants as granule sachets, have become available. We evaluated the effect of Singulair© on clinical progress and on cytokine profiles in the acute phase of RSV bronchiolitis.
Phase:
N/A
Details
Lead Sponsor:
Ziv Hospital
Collaborator:
Wolfson Medical Center
Treatments:
Montelukast
Criteria
Inclusion Criteria:

- Age > 4 weeks < 2 years

- Duration of respiratory symptoms < 4 days

- Signs of bronchiolitis: prodromal rhinorrhea and cough, followed by at least two of
the following signs: chest retractions, tachypnea, wheezing, or rales

- First episode of wheezing or shortness of breath

- Randomization within 12 hours of admission

- No need for steroid treatment in the ward

- Informed consent

Exclusion Criteria:

- A history of asthma symptoms or any previous hospital admissions with respiratory
tract illnesses and if they had ever been treated with anti-asthma medications (prior
to the current illness).

- Underlying cardiopulmonary disease such as bronchopulmonary dysplasia, congenital
heart disease, immunodeficiency, or cystic fibrosis.